Better Tests.

Better Outcomes. Better Technology.

LifeView™ PGT provides the most advanced genetic screening for the IVF embryo available. Studies comparing LifeView to conventional testing methods proved higher pregnancy rates and lower miscarriage rates.

BETTER OUTCOMES

LifeView vs Next-Generation Sequencing

Below is a graph of three different labs that perform preimplantation genetic testing (PGT) on IVF embryos. The orange bar represents Genomic Prediction's Clinical Laboratory where

LifeView is used. The other two bars in the graph represent two other commonly used PGT laboratories.

outcome graphic

OUR TECH

More Euploids,

Lower Loss Rate

A recent publication shows SNP array-based PGT-A has a lower false positive and false negative rate than NGS-based PGT-A. Genomic Prediction was happy to contribute to this study by performing the SNP array-based PGT-A.

Milestones

Studies And Validations

Polygenic risk scores – the technology behind the Embryo Health Score® Test (EHS) – have been around over 15 years, with the last half-decade bringing an explosion of advancements. Polygenic testing is now becoming widely adopted, based on a solid foundation of evidence. The benefit of PGT-P and the EHS is part of these scientific breakthroughs. By using more than 40,000 siblings with full health records,

PGT-P and the EHS have been validated in multiple peer-reviewed publications, proving that it lowers disease risks simultaneously (also among full siblings), can be calculated from a single standard embryo biopsy, and provides benefit for all ancestries.

Recent Publications

Testing Validation

Validation of concurrent preimplantation genetic testing for polygenic and monogenic disorders, structural rearrangements, and whole and segmental chromosome aneuploidy with a single universal platform. European Journal of Medical Genetics August 2019 Treff et al.

Embryo Health Score® Test

Polygenic Health Index, General Health, and Pleiotropy: Sibling Analysis and Disease Risk Reduction. Scientific Reports October 2022 Widen et al.
Should preimplantation genetic testing for polygenic disease be offered to all - or none? Fertility & Sterility June 2022 Treff et al.
Use of Polygenic Scores to Select Embryos. New England Journal of Medicine October 2021 Treff et al.
Embryo Screening for Polygenic Disease Risk: Recent Advances and Ethical Considerations. Genes July 2021 Tellier et al.
Preimplantation genetic testing for polygenic disease risk. Reproduction: The Official Journal of the Society for the Study of Fertility November 2020 Treff et al.
Polygenic risk scoring in the human embryo: reproductive genetics, final frontier? Fertility & Sterility Science August 2020 Treff
Preimplantation Genetic Testing for Polygenic Disease Relative Risk Reduction: Evaluation of Genomic Index Performance in 11,883 Adult Sibling Pairs. Genes June 2020 Treff et al.
Utility and First Clinical Application of Screening Embryos for Polygenic Disease Risk Reduction. Frontiers in Endocrinology December 2019 Treff et al.
Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer. Scientific Reports October 2019 Lello et al.
Validation of concurrent preimplantation genetic testing for polygenic and monogenic disorders, structural rearrangements, and whole and segmental chromosome aneuploidy with a single universal platform. European Journal of Medical Genetics August 2019 Treff et al.

Origin of Aneuploidy or PGT-A+

On the reproductive capabilities of aneuploid human preimplantation embryos. American Journal of Human Genetics September 2022 Capalbo A, Poli M, Jalas C, Forman EJ, Treff NR.
The "mosaic" embryo: misconceptions and misinterpretations in preimplantation genetic testing for aneuploidy. Fertility & Sterility November 2021 Treff and Marin.
Accurate genomic prediction of mosaicism through cell division origin of aneuploidy analysis in the preimplantation embryo. Fertility & Sterility September 2021 Marin et al.
Preimplantation genetic testing for aneuploidy: A review of published blastocyst reanalysis concordance data. Prenatal Diagnosis April 2021 Marin et al.
Isn't it time to stop calling preimplantation embryos "mosaic"? Fertility & Sterility Reports November 2020 Paulson and Treff.

M2

A novel test for annexin A5 M2 haplotyping in in vitro fertilization patients and preimplantation embryos. Fertility & Sterility Science August 2021 Rana et al.

Company Awards

& Media Coverage

Part of our ongoing mission is to truly improve patient care. One of the ways we do that is by continuously taking on research studies and publications.


If you are interested in working on a research project together, let’s connect.


Image of various honors

LifeView™ PGT provides the most ​advanced genetic screening for ​the IVF embryo available. Studies ​comparing LifeView to ​conventional testing methods ​proved higher pregnancy rates ​and lower miscarriage rates.

test symbol

PGT-A

PGT-A screens embryos for aneuploidy so that you and your care team can select an embryo with the correct number of chromosomes (euploid) for transfer, increasing your chances of success and a healthy child.

test symbol

PGT-A+

PGT-A+ is done in conjunction with PGT-A and indicates if the chromosome abnormality originated from the egg (maternal) or sperm (paternal). PGT-A+ requires saliva samples from the patient, partner, and/or gamete donor in addition to embryo samples. 


test symbol

PGT-M

Monogenic disorders are inherited conditions caused by genetic variants in a single gene. PGT-M is designed for individuals who have a higher chance of passing on these types of conditions to their children.


test symbol

Embryo Health Score

The LifeView Embryo Health Score test evaluates genetic variants to assess the risk of polygenic conditions like diabetes, cancer, schizophrenia, and heart disease in your future child. It also helps you and your clinician compare disease risks among embryos to decide which one to prioritize for transfer.

test symbol

PGT-SR

Individuals who are carriers of balanced chromosome rearrangements have a higher chance of creating embryos with extra or missing genetic material. This can lead to fertility problems, pregnancy loss and health issues in an ongoing pregnancy. PGT-SR is designed to select embryos without such chromosome rearrangements for transfer.

test symbol

M2

Biological parents are screened for a gene associated with increased miscarriage risk. Testing for the M2 haplotype is simple and only requires a saliva sample from the biological parents. If the M2 haplotype is present in any of the biological parents it is possible to screen the embryos for the genetic variant.

Partnerships & Collaborations

Used and loved by people at leading companies

Number First Name Last Name Email Address
1 Anne Evans anne.evans@mail.com
2 Bill Fernandez bill.fernandez@mail.com
3 Candice Gates candice.gates@mail.com
4 Dave Hill dave.hill@mail.com